Bengt Hoepken
About
Bengt Hoepken is a scholar working on Rheumatology, Immunology and Hematology.
According to data from OpenAlex, Bengt Hoepken has authored 71 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Rheumatology, 45 papers in Immunology and 14 papers in Hematology. Recurrent topics in Bengt Hoepken's work include Spondyloarthritis Studies and Treatments (58 papers), Psoriasis: Treatment and Pathogenesis (43 papers) and Rheumatoid Arthritis Research and Therapies (41 papers). Bengt Hoepken is often cited by papers focused on Spondyloarthritis Studies and Treatments (58 papers), Psoriasis: Treatment and Pathogenesis (43 papers) and Rheumatoid Arthritis Research and Therapies (41 papers). Bengt Hoepken collaborates with scholars based in Germany, United States and Netherlands. Bengt Hoepken's co-authors include Désirée van der Heijde, Atul Deodhar, Philip J. Mease, C. Stach, Robert Landewé, Walter P. Maksymowych, Martín Rudwaleit, J. Wollenhaupt, Roy Fleischmann and Danuta Kielar and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Quality of Life Research.
In The Last Decade
Bengt Hoepken
64 papers receiving 1.5k citations
Peers
Bengt Hoepken
Wolfgang Thriene Germany
F. Heldmann Germany
R. Besuyen United States
E Taccari Italy
A Linssen Netherlands
M. Schiff United States
Jason Coarse United States
Raquel Campanilho‐Marques Portugal
Giorgio Filosa Italy
Rhonda Shuckett Canada
Citations per year, relative to Bengt Hoepken Bengt Hoepken (= 1×)
peers
Wolfgang Thriene
Countries citing papers authored by Bengt Hoepken
Since
Specialization
Citations
This map shows the geographic impact of Bengt Hoepken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bengt Hoepken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bengt Hoepken more than expected).
Fields of papers citing papers by Bengt Hoepken
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bengt Hoepken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bengt Hoepken. The network helps show where Bengt Hoepken may publish in the future.
Co-authorship network of co-authors of Bengt Hoepken
This figure shows the co-authorship network connecting the top 25 collaborators of Bengt Hoepken. A scholar is included among the top collaborators of Bengt Hoepken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bengt Hoepken. Bengt Hoepken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Langley, Richard G., Mark Lebwohl, Bruce Strober, et al.. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal of the American Academy of Dermatology. 93(3). 644–653.
2.
Proft, Fabian, et al.. (2025). Machine learning vs human experts: sacroiliitis analysis from the RAPID-axSpA and C-OPTIMISE phase 3 axSpA trials. Rheumatology Advances in Practice. 9(2). rkae118–rkae118.
3.
Baraliakos, Xenofon, et al.. (2024). Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis. RMD Open. 10(3). e003886–e003886.
4.
Rudwaleit, Martín, Atul Deodhar, Lars Bauer, et al.. (2024). Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status. RMD Open. 10(2). e003884–e003884.
5.
López‐Medina, Clementina, A. Feydy, Hugues Talbot, et al.. (2024). Performance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases. 84(1). 60–67.
6.
Kokolakis, Georgios, Mark Lebwohl, Peter Foley, et al.. (2024). AB0490 BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHT. Annals of the Rheumatic Diseases. 83. 1513–1513.
7.
Youn, Sang Woong, Seong Jin Jo, Chul Jong Park, et al.. (2024). Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study. The Journal of Dermatology. 51(11). 1392–1403.
8.
Blauvelt, Andrew, Peter Foley, Richard G. Langley, et al.. (2024). Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 8(6). s437–s437.
9.
Heijde, Désirée van der, Lianne S. Gensler, Walter P. Maksymowych, et al.. (2022). Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 8(1). e002138–e002138.
10.
Landewé, Robert, Désirée van der Heijde, Maxime Dougados, et al.. (2020). Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases. 79(7). 920–928.
11.
Horst‐Bruinsma, Irene van der, Frank D. Verbraak, Timo Räth, et al.. (2020). The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 6(1). e001161–e001161.
12.
Baraliakos, Xenofon, Torsten Witte, Luc S. De Clerck, et al.. (2020). Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. Lara D. Veeken. 60(1). 113–124.
13.
Heijde, Désirée van der, Atul Deodhar, Oliver FitzGerald, et al.. (2018). 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 4(1). e000582–e000582.
14.
Heijde, Désirée van der, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2018). Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases. 77(5). 699–705.
15.
Mease, Philip J., Roy Fleischmann, J. Wollenhaupt, et al.. (2016). CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL. Clinical and Experimental Rheumatology. 34(4). 779–780.
16.
Mease, Philip, et al.. (2014). Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure. Data Archiving and Networked Services (DANS).
17.
Maksymowych, Walter P., R. Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The Journal of Rheumatology. 41(7). 1496–1497.
18.
Mease, Philip, R Fleischmann, J. Wollenhaupt, et al.. (2013). EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. Lara D. Veeken. 52(10). 162–163.
19.
Wollenhaupt, J., D. Gladman, C. Stach, et al.. (2013). Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. The Journal of Rheumatology. 41(7). 1448–1449.
20.
Landewé, Robert, Martín Rudwaleit, Désirée van der Heijde, et al.. (2012). Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study. Data Archiving and Networked Services (DANS). 64(10).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wolfgang Thriene Breakdown of academic impact, for papers by F. Heldmann Breakdown of academic impact, for papers by R. Besuyen Breakdown of academic impact, for papers by E Taccari Breakdown of academic impact, for papers by A Linssen Breakdown of academic impact, for papers by M. Schiff Breakdown of academic impact, for papers by Jason Coarse Breakdown of academic impact, for papers by Raquel Campanilho‐Marques Breakdown of academic impact, for papers by Giorgio Filosa Breakdown of academic impact, for papers by Rhonda Shuckett